Fungal Species: Psilocybin-containing mushrooms (species not specified)

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial

mycolabadmin

Researchers tested whether combining psilocybin therapy with mindfulness training could better treat depression and burnout in frontline healthcare workers than mindfulness training alone. Twenty-five doctors and nurses participated in the study, with some receiving mindfulness training combined with psilocybin therapy in a group setting, while others received mindfulness training only. After two weeks, those who received the combined treatment showed significantly greater improvements in depression symptoms and burnout, with no serious side effects reported. This suggests that psilocybin-assisted therapy combined with mindfulness training could be a promising treatment for depression and burnout among healthcare professionals.

Read More »

Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective

mycolabadmin

This scientific commentary examines how research on psychedelic-assisted therapy for eating disorders may be missing important aspects of how people actually experience the treatment. The authors argue that current study methods rely too heavily on questionnaires that don’t capture the full depth of what people experience during psychedelic sessions. They propose using phenomenological approaches—methods that deeply explore lived experience—to better understand which aspects of the psychedelic experience actually lead to recovery from eating disorders.

Read More »

Love (Drugs), Happiness, and Morality

mycolabadmin

This paper argues that love, happiness, and moral behavior create a self-reinforcing cycle: moral actions increase happiness, happiness promotes loving feelings, and love encourages more moral behavior. The author proposes that psilocybin and other love-enhancing drugs could strengthen this beneficial cycle, making them an ethical way for people to voluntarily improve themselves and society without requiring government mandates.

Read More »

Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study

mycolabadmin

Researchers investigated whether psilocybin, a compound from certain mushrooms, could be safely used to treat memory problems in older adults with mild cognitive impairment. In this early-stage study, participants received either psilocybin or a placebo while researchers used brain imaging to measure changes in synaptic connections. The preliminary results suggest psilocybin was well-tolerated with manageable side effects like dizziness, and participants were able to complete the study without serious problems.

Read More »
Scroll to Top